CDC20 p.Arg479Trp
c.1435C>T · VCV3264934
Computational evidence
| Protein change | ||
| AlphaMissense | 0.2759 | likely benign |
|---|---|---|
| REVEL | 0.078 | moderately benign-leaning |
| SaProt | LLR -10.82 | damaging |
| ⇒ SaProt calls this damaging; AlphaMissense and REVEL do not. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
| Constraint at this position | ||
| Conservation | phyloP 1.4 | GERP 1.1, phastCons 0.78 |
| Regional constraint | o/e 0.92 | unconstrained · MANE · 162 bp · p 0.5 · regional, not allelic |
| Overall | ||
| CADD | 25.5 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| Remaining individualsnot grpmax-eligible | 0.0048% | 20,825 |
| South Asiangrpmax | 0.0044% | 22,740 |
| Admixed American | 0.00334% | 29,915 |
| European (non-Finnish) | 0.00331% | 30,254 |
| African / African-American | 0.00267% | 37,444 |
| East Asian | 0.00223% | 44,884 |
Remaining individuals shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- CDC20
- Protein
- p.Arg479Trp
- Coding
- c.1435C>T
- MANE Select
- NM_001255
- Type
- single nucleotide variant
- Location
- chr1:43363064 (GRCh38)
- Gene constraint
- LOEUF 0.744 · pLI <0.01 (gnomAD)
- Structure
- AlphaFold pLDDT 84.39 · 17 PDB
- Residue 479
- a UniProt-annotated variant site (in ozema14; severely decreased function in metaphase/anaphase transition of meiosis i; does not fully rescue metaphase i arrest in cdc20-knocked down mouse oocytes; decreased function in positive regulation of anaphase-promoting complex-dependent catabolic process; fails to localize to the kinetochore); a UniProt-annotated variant site (in ozema14); a UniProt-annotated variant site (in)
Similar variants
- CDC20 p.Glu484= Benign ★★ same type
- CDC20 p.Val361Ile Benign/Likely benign ★★ same type
- CDC20 p.Cys364Ter Likely pathogenic ★ same type
- CDC20 c.556+1G>T Conflicting classifications of pathogenicity ★ same type
- CDC20 p.Ala140Val Uncertain significance ★ ⚠ same type
- CDC20 p.Ala242Val Uncertain significance ★ ⚠ same type
- CDC20 p.Ala461Thr Uncertain significance ★ ⚠ same type
- CDC20 p.Arg162Gly Uncertain significance ★ ⚠ same type
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/cdc20-p-arg479trp (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown